Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score

Yu-Tzu Chang, Jing-Shiang Hwang, Shih-Yuan Hung, Min-Sung Tsai, Jia-Ling Wu, Junne-Ming Sung, Jung-Der Wang, Yu-Tzu Chang, Jing-Shiang Hwang, Shih-Yuan Hung, Min-Sung Tsai, Jia-Ling Wu, Junne-Ming Sung, Jung-Der Wang

Abstract

Although treatment for the dialysis population is resource intensive, a cost-effectiveness analysis comparing hemodialysis (HD) and peritoneal dialysis (PD) by matched pairs is still lacking. After matching for clinical characteristics and propensity scores, we identified 4,285 pairs of incident HD and PD patients from a Taiwanese national cohort during 1998-2010. Survival and healthcare expenditure were calculated by data of 14-year follow-up and subsequently extrapolated to lifetime estimates under the assumption of constant excess hazard. We performed a cross-sectional EQ-5D survey on 179 matched pairs of prevalent HD and PD patients of varying dialysis vintages from 12 dialysis units. The product of survival probability and the mean utility value at each time point (dialysis vintage) were summed up throughout lifetime to obtain the quality-adjusted life expectancy (QALE). The results revealed the estimated life expectancy between HD and PD were nearly equal (19.11 versus 19.08 years). The QALE's were also similar, whereas average lifetime healthcare costs were higher in HD than PD (237,795 versus 204,442 USD) and the cost-effectiveness ratios for PD and HD were 13,681 and 16,643 USD per quality-adjusted life year, respectively. In conclusion, PD is more cost-effective than HD, of which the major determinants were the costs for the dialysis modality and its associated complications.

Figures

Figure 1. Flow diagram of establishing the…
Figure 1. Flow diagram of establishing the study cohorts and cross-sectional samples followed by matching on clinical characteristics and propensity scores for patients under hemodialysis (HD) and peritoneal dialysis (PD) to estimate quality-adjusted life expectancy (QALE) and lifetime costs.
Abbreviation: ESRD: end-stage renal disease; QALE: quality-adjusted life expectancy; QALY: quality-adjusted life year.
Figure 2. Estimation of quality-adjusted life expectancy…
Figure 2. Estimation of quality-adjusted life expectancy (QALE) for patients under hemodialysis (HD) and peritoneal dialysis (PD).
Lifetime survival curves of HD and PD were depicted in the black and red lines, respectively. The QALE was estimated by summarizing the total area under the survival curve.
Figure 3
Figure 3
(a) Average monthly costs for inpatient and outpatient healthcare expenditures and (b) monthly proportions of outpatient costs within total healthcare expenditures of patients selected from 1:1 matched hemodialysis (HD) and peritoneal dialysis (PD) during the follow-up period.

References

    1. Meguid El Nahas A. & Bello A. K. Chronic kidney disease: the global challenge. Lancet 365, 331–340, 10.1016/S0140-6736(05)17789-7 (2005).
    1. Klarenbach S. W., Tonelli M., Chui B. & Manns B. J. Economic evaluation of dialysis therapies. Nat. Rev. Nephrol. 10, 644–652, 10.1038/nrneph.2014.145 (2014).
    1. US Renal Data System. USRDS 2014. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, 2014. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Available at: (Accessed: 17 August 2015).
    1. Levey A. S. et al.. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 72, 247–259, 10.1038/sj.ki.5002343 (2007).
    1. US Renal Data System. USRDS 2007. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, 2007. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Available at: (Accessed: 17 August 2015).
    1. National Health Research Institute. 2014 Annual Report on Kidney Disease in Taiwan. Available at: (Accessed: 10 June 2016).
    1. Haller M., Gutjahr G., Kramar R., Harnoncourt F. & Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol. Dial. Transplant. 26, 2988–2995, 10.1093/ndt/gfq780 (2011).
    1. Howard K. et al.. The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology (Carlton) 14, 123–132, 10.1111/j.1440-1797.2008.01073.x (2009).
    1. Chanouzas D., Ng K. P., Fallouh B. & Baharani J. What influences patient choice of treatment modality at the pre-dialysis stage? Nephrol. Dial. Transplant. 27, 1542–1547, 10.1093/ndt/gfr452 (2012).
    1. Davies S. J. Peritoneal dialysis–current status and future challenges. Nat. Rev. Nephrol. 9, 399–408, 10.1038/nrneph.2013.100 (2013).
    1. Li P. K. & Chow K. M. Peritoneal dialysis-first policy made successful: perspectives and actions. Am. J. Kidney Dis. 62, 993–1005, 10.1053/j.ajkd.2013.03.038 (2013).
    1. Kao T. W. et al.. Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan. Perit. Dial. Int. 33, 671–678, 10.3747/pdi.2012.00081 (2013).
    1. Peeters P., Rublee D., Just P. M. & Joseph A. Analysis and interpretation of cost data in dialysis: review of Western European literature. Health Policy 54, 209–227, 10.1016/S0168-8510(00)00112-3 (2000).
    1. McDonald S. P., Marshall M. R., Johnson D. W. & Polkinghorne K. R. Relationship between dialysis modality and mortality. J. Am. Soc. Nephrol. 20, 155–163, 10.1681/ASN.2007111188 (2009).
    1. Collins A. J. et al.. Mortality risks of peritoneal dialysis and hemodialysis. Am. J. Kidney Dis. 34, 1065–1074, 10.1016/S0272-6386(99)70012-0 (1999).
    1. Murphy S. W. et al.. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int. 57, 1720–1726, 10.1046/j.1523-1755.2000.00017.x (2000).
    1. Ganesh S. K., Hulbert-Shearon T., Port F. K., Eagle K. & Stack A. G. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J. Am. Soc. Nephrol. 14, 415–424, 10.1097/01.ASN.0000043140.23422.4F (2003).
    1. Stack A. G., Molony D. A., Rahman N. S., Dosekun A. & Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int. 64, 1071–1079, 10.1046/j.1523-1755.2003.00165.x (2003).
    1. Vonesh E. F., Snyder J. J., Foley R. N. & Collins A. J. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int. 66, 2389–2401, 10.1111/j.1523-1755.2004.66028.x (2004).
    1. Jaar B. G. et al.. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann. Intern. Med. 143, 174–183, 10.7326/0003-4819-143-3-200508020-00003 (2005).
    1. Weinhandl E. D. et al.. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J. Am. Soc. Nephrol. 21, 499–506, 10.1681/ASN.2009060635 (2010).
    1. Nelson C. B., Port F. K., Wolfe R. A. & Guire K. E. Comparison of continuous ambulatory peritoneal dialysis and hemodialysis patient survival with evaluation of trends during the 1980s. J. Am. Soc. Nephrol. 3, 1147–1155 (1992).
    1. Mehrotra R., Chiu Y. W., Kalantar-Zadeh K., Bargman J. & Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch. Intern. Med. 171, 110–118, 10.1001/archinternmed.2010.352 (2011).
    1. Liem Y. S., Wong J. B., Hunink M. G., de Charro F. T. & Winkelmayer W. C. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int. 71, 153–158, 10.1038/sj.ki.5002014 (2007).
    1. Lukowsky L. R. et al.. Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. Clin. J. Am. Soc. Nephrol. 8, 619–628, 10.2215/CJN.04810512 (2013).
    1. Kim H. et al.. A population-based approach indicates an overall higher patient mortality with peritoneal dialysis compared to hemodialysis in Korea. Kidney Int. 86, 991–1000, 10.1038/ki.2014.163 (2014).
    1. Kumar V. A., Sidell M. A., Jones J. P. & Vonesh E. F. Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system. Kidney Int. 86, 1016–1022, 10.1038/ki.2014.224 (2014).
    1. Harris S. A., Lamping D. L., Brown E. A. & Constantinovici N. North Thames Dialysis Study, G. Clinical outcomes and quality of life in elderly patients on peritoneal dialysis versus hemodialysis. Perit. Dial. Int. 22, 463–470 (2002).
    1. Korevaar J. C. et al.. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int. 64, 2222–2228, 10.1046/j.1523-1755.2003.00321.x (2003).
    1. Manns B. et al.. Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin. Nephrol. 60, 341–351, 10.5414/CNP60341 (2003).
    1. Kutner N. G., Zhang R., Barnhart H. & Collins A. J. Health status and quality of life reported by incident patients after 1 year on haemodialysis or peritoneal dialysis. Nephrol. Dial. Transplant. 20, 2159–2167, 10.1093/ndt/gfh973 (2005).
    1. Wu A. W. et al.. Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire. Am. J. Kidney Dis. 37, 11–21, 10.1053/ajkd.2001.20631 (2001).
    1. Wasserfallen J. B. et al.. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol. Dial. Transplant. 19, 1594–1599, 10.1093/ndt/gfh175 (2004).
    1. Cameron J. I., Whiteside C., Katz J. & Devins G. M. Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am. J. Kidney Dis. 35, 629–637, 10.1016/S0272-6386(00)70009-6 (2000).
    1. Wyld M., Morton R. L., Hayen A., Howard K. & Webster A. C. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 9, e1001307, 10.1371/journal.pmed.1001307 (2012).
    1. Just P. M. et al.. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol. Dial. Transplant. 23, 2365–2373, 10.1093/ndt/gfm939 (2008).
    1. Bureau of National Health Insurance. 2001. National Health Insurance Annual Statistical Report. Taipei, Taiwan, 2002).
    1. Lin C. C., Lai M. S., Syu C. Y., Chang S. C. & Tseng F. Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J. Formos. Med. Assoc. 104, 157–163 (2005).
    1. Chang Y. T., Wu J. L., Hsu C. C., Wang J. D. & Sung J. M. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998–2009. Diabetes Care 37, 277–285, 10.2337/dc13-0781 (2014).
    1. Chen H. F., Chen P. & Li C. Y. Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. Hepatology 52, 155–163, 10.1002/hep.23641 (2010).
    1. Wang H. H., Hung S. Y., Sung J. M., Hung K. Y. & Wang J. D. Risk of stroke in long-term dialysis patients compared with the general population. Am. J. Kidney Dis. 63, 604–611, 10.1053/j.ajkd.2013.10.013 (2014).
    1. Rabin R. & de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann. Med. 33, 337–343, 10.3109/07853890109002087 (2001).
    1. Dolan P. Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108, 10.1097/00005650-199711000-00002 (1997).
    1. Rosenbaum P. R. R. D. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41–55, 10.1093/biomet/70.1.41 (1983).
    1. Rosenbaum P. R. R. D. Reducing bias in observational studies using subclassification on the propensity score. J. Am. Stat. Assoc. 79, 516–524, 10.1080/01621459.1984.10478078 (1984).
    1. Tan H. F., Tseng H. F., Chang C. K., Lin W. & Hsiao S. H. Accessibility assessment of the Health Care Improvement Program in rural Taiwan. J. Rural Health 21, 372–377, 10.1111/j.1748-0361.2005.tb00110.x (2005).
    1. Moreno F., Lopez Gomez J. M., Sanz-Guajardo D., Jofre R. & Valderrabano F. Quality of life in dialysis patients. A spanish multicentre study. Spanish Cooperative Renal Patients Quality of Life Study Group. Nephrol. Dial. Transplant. 11 Suppl 2, 125–129, 10.1093/ndt/11.supp2.125 (1996).
    1. Mingardi G. et al.. Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey. DIA-QOL Group. Nephrol. Dial. Transplant. 14, 1503–1510, 10.1093/ndt/14.6.1503 (1999).
    1. Baiardi F. et al.. Effects of clinical and individual variables on quality of life in chronic renal failure patients. J. Nephrol. 15, 61–67 (2002).
    1. Yang S. C., Kuo P. W., Wang J. D., Lin M. I. & Su S. Quality of life and its determinants of hemodialysis patients in Taiwan measured with WHOQOL-BREF(TW). Am. J. Kidney Dis. 46, 635–641, 10.1053/j.ajkd.2005.06.015 (2005).
    1. Hwang J. S. & Wang J. D. Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat. Med. 18, 1627–1640, 10.1002/(SICI)1097-0258(19990715)18:13<1627::AID-SIM159>;2-D (1999).
    1. Fang C. T. et al.. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 100, 97–105, 10.1093/qjmed/hcl141 (2007).
    1. Life tables for Repubic of China (Taiwan). Available at: . (Accessed: 17 April 2016).
    1. Hwang J. S. iSQoL software: A software used for integration of Survival with Quality of Life. Taipei, Taiwan. Available at: (Accessed: 17 August 2015) (2014).
    1. Lee H. Y., Hwang J. S., Jeng J. S. & Wang J. D. Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke 41, 739–744, 10.1161/STROKEAHA.109.573543 (2010).
    1. Chu P. C., Wang J. D., Hwang J. S. & Chang Y. Y. Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high-censored rates. Value Health 11, 1102–1109, 10.1111/j.1524-4733.2008.00350.x (2008).
    1. Hung M. C. et al.. Life expectancies and incidence rates of patients under prolonged mechanical ventilation: a population-based study during 1998 to 2007 in Taiwan. Crit. Care 15, R107, 10.1186/cc10128 (2011).
    1. Chang K. C. et al.. Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan. Drug Alcohol. Depend. 153, 152–158, 10.1016/j.drugalcdep.2015.05.033 (2015).
    1. Yang D. C. et al.. Estimation of expected life-years saved from successful prevention of end-stage renal disease in elderly patients with diabetes: a nationwide study from Taiwan. Diabetes Care 35, 2279–2285, 10.2337/dc12-0545 (2012).
    1. Kao T. W. et al.. Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients. J. Nephrol. 23, 677–682 (2010).
    1. Hung M. C., Sung J. M., Chang Y. T., Hwang J. S. & Wang J. D. Estimation of physical functional disabilities and long-term care needs for patients under maintenance hemodialysis. Med. Care 52, 63–70, 10.1097/MLR.0000000000000010 (2014).
    1. Hwang J. S., Tsauo J. Y. & Wang J. D. Estimation of expected quality adjusted survival by cross-sectional survey. Stat. Med. 15, 93–102, 10.1002/(SICI)1097-0258(19960115)15:1<93::AID-SIM155>;2-2 (1996).
    1. Choosing interventions that are cost-effective. Geneva: World Health Organization. Available at: . (Accessed: 17 March 2016).
    1. Lee H. Y. et al.. Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan. J. Formos. Med. Assoc. 112, 699–706, 10.1016/j.jfma.2012.12.015 (2013).
    1. Vonesh E. F., Snyder J. J., Foley R. N. & Collins A. J. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int. Suppl. S3–11, 10.1038/sj.ki.5001910 (2006).
    1. Jager K. J. et al.. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am. J. Kidney Dis. 43, 891–899, 10.1053/j.ajkd.2003.12.051 (2004).
    1. Mehrotra R., Marsh D., Vonesh E., Peters V. & Nissenson A. Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. Kidney Int. 68, 378–390, 10.1111/j.1523-1755.2005.00453.x (2005).
    1. Little J., Irwin A., Marshall T., Rayner H. & Smith S. Predicting a patient’s choice of dialysis modality: experience in a United Kingdom renal department. Am. J. Kidney Dis. 37, 981–986, 10.1016/S0272-6386(05)80014-9 (2001).
    1. Sennfalt K., Magnusson M. & Carlsson P. Comparison of hemodialysis and peritoneal dialysis–a cost-utility analysis. Perit. Dial. Int. 22, 39–47 (2002).
    1. Villa G. et al.. Cost-effectiveness analysis of the Spanish renal replacement therapy program. Perit. Dial. Int. 32, 192–199, 10.3747/pdi.2011.00037 (2012).
    1. Shih Y. C., Guo A., Just P. M. & Mujais S. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int. 68, 319–329, 10.1111/j.1523-1755.2005.00413.x (2005).
    1. St Peter W. L., Khan S. S., Ebben J. P., Pereira B. J. & Collins A. J. Chronic kidney disease: the distribution of health care dollars. Kidney Int. 66, 313–321, 10.1111/j.1523-1755.2004.00733.x (2004).
    1. Wu A. W. et al.. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. J. Am. Soc. Nephrol. 15, 743–753, 10.1097/ (2004).
    1. Merkus M. P. et al.. Quality of life over time in dialysis: the Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int. 56, 720–728, 10.1046/j.1523-1755.1999.00563.x (1999).
    1. Liem Y. S., Bosch J. L. & Hunink M. G. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health 11, 733–741, 10.1111/j.1524-4733.2007.00308.x (2008).
    1. Fukuhara S. et al.. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 64, 1903–1910, 10.1046/j.1523-1755.2003.00289.x (2003).
    1. “National Health Expenditure 2012”. Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan. Available at: . (Accessed: 17 August 2015).
    1. Healthcare expenditure per capita (Current US$). The World Bank. Available at: . (Accessed: 17 August 2015).

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere